Stifel initiated coverage of Ra Pharmaceuticals (NASDAQ:RARX) with a “buy” rating and $55 price target. The stock closed at $19.87 on Feb. 7. Ra Pharma uses a proprietary peptide chemistry platform to develop...

SVB Leerink downgraded Solid Biosciences (NASDAQ:SLDB) to “market perform” from “outperform” and slashed its price target to $8 from $50 after the company reported disappointing Phase 1/2 data from its experimental gene...

Dawson James Securities initiated coverage of BioTime (NYSE American:BTX) with a “buy” rating and $6 price target. The stock closed at $1.16 on Feb. 6. “We view BioTime as a new company invigorated by a new management...

SVB Leerink launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with an “outperform” rating and sum-of-the-parts price target of $10. The stock closed at $3.66 on Feb. 5. Analyst Marc Goodman writes that his...

H.C. Wainwright raised its price target for Trevena (NASDAQ:TRVN) to $1.25 from 75 cents, saying that resolution on two clinical requests from the FDA paves a path for the company’s NDA resubmission for oliceridine, a...

H.C. Wainwright lowered its price target for Rexahn Pharmaceuticals (NYSE American:PNN) to $10 from $17 to reflect a higher number of shares outstanding after an equity issue in January. The stock closed at 63 cents on...

Analyst at Leerink and H.C. Wainwright lowered their price targets for AC Immune (NASDAQ:ACIU) after the company’s partner, Roche/Genentech, discontinued the Phase 3 CREAD 1 and 2 trials of crenezumab for the treatment...

H.C. Wainwright downgraded AVEO Pharmaceuticals (NASDAQ:AVEO) to “neutral” from “buy” and slashed its price target to $1 from $9 after the FDA recommended against the filing of a tivozanib NDA, citing the lack of...

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Mesoblast (NASDAQ:MESO) with a “buy” rating and price target of $6.50. The stock closed at $4.56 on Jan. 30. Australia-based Mesoblast is focused on...

Leerink downgraded scPharmaceuticals (NASDAQ:SCPH) to “market perform” from “outperform” and slashed its price target to $5 from $12 after the company inked a deal to use West Pharmaceuticals’ SmartDose on-body drug...

Stifel launched coverage of Evolus (NASDAQ:EOLS) with a “buy” rating and 12-month price target of $27. The stock closed at $14.99 on Jan. 28. “Evolus’ success hinges on the potential for Jeuveauto serve as an...

Roth Capital Partners analyst Jotin Marango resumed coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $10 price target. The stock closed at $1.82 on Jan. 25. “We like the breadth and optionality of...

H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of IsoRay (NYSE American:ISR) with a “buy” rating and price target of 70 cents, saying the company is “at an inflection point of sustainable revenue growth...

Roth Capital Partners launched coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and price target of $10.50. The stock closed at $2.25 on Jan. 25. AzurRx is developing non-systemic, recombinant enzyme...

Paradigm Capital launched coverage of CannTrust Holdings (TSX:TRST) with a “buy” rating and $18 price target. The stock closed at $8.35 on Jan.18. “CannTrust brings to the cannabis space a practice of professionalism...

H.C. Wainwright raised its price target for Aeterna Zentaris (NASDAQ, TSX:AEZS) to $5.50 from $3 after its Macrilen agent for adult growth hormone deficiency (AGHD) was approved for sale in the EU. The stock closed at...

Leerink launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “market perform” rating and $21 price target. The stock closed at $25.33 on Jan. 16. Puma is a single-product commercial-stage biotech company...

Echelon Wealth Partners initiated coverage of Kalytera Therapeutics (TSXV:KALY) with a “speculative buy” rating and price target of 30 cents. The stock closed at 8.5 cents on Jan. 14. Kalytera is developing the...